MedWatch

Novo Nordisk applies for label extension for diabetes treatment

Novo Nordisk will now also apply to the EU for a new and higher dose of the drug Ozempic, which is has already been approved for treating type 2 diabetes.

Photo: Novo Nordisk / PR

Novo Nordisk plans to expand its selection of doses in which the firm may sell the diabetes drug Ozempic. Recently, this resulted in an application to the European Medicines Agency for extending the current label, according to the company's press announcement.

Currently, Ozempic is approved for treating type 2 diabetes in doses of 0.5 mg and 1.0 mg, but Novo Nordisk also wishes to apply for the approval of a 2.0 mg dose.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs